ABL1 and acute lymphoblastic leukemia: This advantage is particularly important for BCR-ABL1 like ALL because the ELISA assay conditions could be optimized regardless of the specific chimeric protein encoded by the genetic abnormalities in BCR-ABL like leukemic cells of the ABL-class.